Literature DB >> 26870605

The Daniel K. Inouye College of Pharmacy Scripts: Prescription Drug Pricing.

Wesley K Sumida1, Ronald Taniguchi1, Deborah Taira Juarez1.   

Abstract

Prescription drugs have reduced morbidity and mortality and improved the quality of life of millions of Americans. Yet, concerns over drug price increases loom. Drug spending has risen relatively slowly over the past decade because many of the most popular brand-name medicines lost patent protection. In the near future, there will be fewer low-cost generics coming into the market to offset the rising prices of brand-name drugs. Drug expenditures are influenced by both volume and price. This article focuses on how drug prices are set in the United States and current trends. Drug prices are determined through an extremely complicated set of interactions between pharmaceutical manufacturers, wholesalers, retailers, insurers, pharmacy benefit managers (PBMs), managed care organizations, hospitals, chain stores, and consumers. The process differs depending on the type of drug and place of delivery. Rising drug prices have come under increased scrutiny due to increased cost inflation and because many price increases come as a result of mergers and acquisitions of generic drug companies or changes in ownership of brand name drug manufacturers. Other countries have reigned in drug prices by negotiating with or regulating pharmaceutical manufacturers. The best long-term solution to rising drug prices is yet to be determined but the United States will continue to debate this issue and the discussions will get more heated if drug expenditures continue to rise at a rapid rate (ie, increasing 13% in 2014 from the previous year).

Mesh:

Substances:

Year:  2016        PMID: 26870605      PMCID: PMC4733824     

Source DB:  PubMed          Journal:  Hawaii J Med Public Health        ISSN: 2165-8242


  5 in total

1.  Biosimilars: Implications for health-system pharmacists.

Authors:  Steven D Lucio; James G Stevenson; James M Hoffman
Journal:  Am J Health Syst Pharm       Date:  2013-11-15       Impact factor: 2.637

2.  Higher US branded drug prices and spending compared to other countries may stem partly from quick uptake of new drugs.

Authors:  Panos Kanavos; Alessandra Ferrario; Sotiris Vandoros; Gerard F Anderson
Journal:  Health Aff (Millwood)       Date:  2013-04       Impact factor: 6.301

3.  U.S. pharmaceutical policy in a global marketplace.

Authors:  Darius N Lakdawalla; Dana P Goldman; Pierre-Carl Michaud; Neeraj Sood; Robert Lempert; Ze Cong; Han de Vries; Italo Gutierrez
Journal:  Health Aff (Millwood)       Date:  2008-12-16       Impact factor: 6.301

4.  The effect of regulation on pharmaceutical revenues: experience in nineteen countries.

Authors:  Neeraj Sood; Han de Vries; Italo Gutierrez; Darius N Lakdawalla; Dana P Goldman
Journal:  Health Aff (Millwood)       Date:  2008-12-16       Impact factor: 6.301

5.  The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?

Authors:  Daniel M Hartung; Dennis N Bourdette; Sharia M Ahmed; Ruth H Whitham
Journal:  Neurology       Date:  2015-04-24       Impact factor: 9.910

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.